Heterogeneity and Risk-of-Biases are No Longer the Issues to Conclude the Effectiveness of Baricitinib in Reducing COVID-19 Related Mortality: A Systematic Review and Meta-Analysis of Eight Randomised Controlled Trials

Sivananthan Manoharan¹* & Lee Ying Ying²

¹Molecular Pathology Unit, Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health Malaysia, Setia Alam, 40170 Shah Alam, Selangor, Malaysia.
²Asia Metropolitan University, Bandar Baru Seri Alam, 81750 Johor Bahru, Johor, Malaysia.

*Phone: +60333627498; Email: sivananthan@moh.gov.my

Abstract

Background: Due to high heterogeneity and risk of bias (RoB) in previously published meta-analysis, a concrete conclusion on the efficacy of baricitinib in reducing mortality in COVID-19 patients was unable to form.

Methods: Search engines PubMed/MEDLINE, ScienceDirect and other sources like preprints and reference lists were searched with appropriate keywords. The included evidence was graded with GRADEpro. The RoB, heterogeneity and meta-analysis were studied through RevMan 5.4.1 software. The heterogeneity was evaluated based on the generated $p$-value or $I^2$ test.

Results: Eight (8) RCTs were included in current analysis. Five studies had low RoB. Based on grading the evidence, the inclusion and exclusion of high RoB articles led to moderate and high certainty of evidence, respectively. Based on 8 RCTs (with high RoB), baricitinib statistically significantly reduced mortality where the risk ratio (RR) = 0.84 [95% CI: 0.76 to 0.92; $p = 0.0002$; $I^2 = 23\%$; $p = 0.25$]. The heterogeneity was insignificant but the RoB was high. We did subgroup analysis of low and high RoB articles and found out baricitinib statistically significantly reduced mortality with the RR = 0.68 [95% CI: 0.56 to 0.82; $p < 0.0001$; $I^2 = 0\%$; $p = 0.85$] and RR = 0.89 [95% CI: 0.80 to 0.99; $p = 0.04$; $I^2 = 0\%$; $p = 0.43$], respectively. The heterogeneity was 0% with insignificant $p$-values in both subgroup analyses. The percentage of mortality reduction was 31.31% and 7.79%, respectively whereas it was 13.95% in main group analysis.

Conclusion: With the presence of optimal sample size of 3944 from 5 low RoB studies which represents a minimum of 300 million population of people and with 0% of heterogeneity, the effectiveness of baricitinib in reducing the mortality in COVID-19 patients is concretely proven.

Keywords: Baricitinib; COVID-19; Meta-analysis; Mortality; Randomised controlled trials

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
1. Introduction

As of 06 November 2022, approximately 637 million of total COVID-19 cases have been reported worldwide which resulted in more than 6.6 million deaths [1]. The emergence of SARS-CoV-2 variants like Alpha, Beta, Gamma, Delta and Omicron further challenges the healthcare systems. The continuous efforts are being made by the scientists to discover new therapies for global citizens who are infected with SARS-CoV-2 virus. One of the strategies was to repurpose an anti-rheumatoid arthritis drug, baricitinib for the management of COVID-19 patients. Baricitinib, a Januse Kinase 1 (JAK 1) and 2 (JAK 2) inhibitor is the first immunomodulator which was found to reduce the mortality (death) in COVID-19 patients. Baricitinib was revealed to decrease various cytokines and biomarkers involved in COVID-19 pathophysiology. This drug is available in tablet form and due to its affordability, they are used in low and middle-income nations [2-3]. A recent meta-analysis (MA) based on 4 RCTs reported that baricitinib statistically significantly reduced mortality in COVID-19 patients [4]. In this MA, the authors had included RECOVERY study related data where RECOVERY study was an open label study which subject to high risk of bias (RoB). Furthermore, based on the MA analysis for mortality, the heterogeneity ($I^2$) was significant with $I^2 = 65\%$ and $p$-value = 0.04. When the RoB and heterogeneity are high/significant, the data need to be interpreted carefully. With the availability of latest ACTT-4 and several more RCTs data related to mortality, the MA needs to be updated in order to guide the clinicians with latest information related to baricitinib for the management of COVID-19 disease. In current work, the authors updated the systematic review (SR) and MA with the latest mortality data from 4 RCTs with the aim to derive a clear-cut conclusion for mortality.

2. Methodology

In the latest SR and MA, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed in order to shape this review. The guidelines were followed accordingly. No advanced protocol associated to the latest SR and MA was made or registered.

2.1 Research questions

1. What is the statistical ability of baricitinib to reduce mortality/death in COVID-19 patients?

2. Does heterogeneity and RoB remain as obstacles to derive a clear-cut conclusion for mortality?
2.2 Search strategies, article eligibility criteria and data charting process

Two well-known databases, known as PubMed/MEDLINE, ScienceDirect and additional sources, such as preprints and reference list were explored systematically with keywords, specifically ‘Randomised controlled trials baricitinib COVID-19; Randomised controlled trials baricitinib SARS-CoV-2 virus; and Randomised controlled trials baricitinib pneumonia’. The search was done manually in preprint and reference list. The searched year was in between 2020 and 30 October 2022. The inclusion criteria were:

(i) Patients disease-ridden with SARS-CoV-2 virus;
(ii) Baricitinib was used for intervention purposes;
(iii) Compulsory existence of proper control/s;
(iv) Stringently only for RCT works;
(v) Clinical efficacy mentioned in the study results; and
(vi) Language restriction: Only English language articles.

The data charting process were undertaken entirely by two authors, independently. Both authors had no issue with any shortlisted articles and thus, not requiring the third person’s involvement to resolve the problem.

2.3 Risk of bias analysis (RoB), grading the evidence using GRADEpro and conduct of MA

The Cochrane RoB tool was used to determine the quality of RCTs [5]. Moreover, the authors conducted an additional step to grade the quality of the included articles with GRADEpro Guideline Development Tool software [6]. The MA was conducted via Review Manager 5.4.1 [5]. Dichotomous data type was selected. The data related to RCTs were pooled, and relative risk, confidence interval (CI) and Mantel-Haenszel statistical methods were employed. The heterogeneity was evaluated based on the generated $p$-value, the $I^2$ test. Heterogeneity was considered as significant when $p<0.1$ or $I^2>50$% [7]. A fixed-effect or random-effect model was selected when the data were homogeneous or heterogeneous, respectively. The publication bias (PB) was not studied because only eight articles were available. A minimum of ten articles are needed to yield a good statistical related funnel plot to detect PB.

3. Results and discussions
Based on the literature search, 8 RCT articles were included in qualitative and quantitative analyses. Table 1 was adopted and modified from the authors’ own published MA manuscript in the Canadian Journal of Infectious Diseases and Medical Microbiology [8]. Based on table 1, baricitinib was divided into 2 doses known as 2 mg or 4 mg (depending on the health of the patients) and was given to the included COVID-19 participants for maximum of 14 days. The age of the participants in both groups was consistent in all studies except for 2 open labelled studies. But the age is consistent in all full RCTs with low RoB. This consistency is important in order to derive a good conclusion. Although some little variations in genetics may present in the overall study populations (about 0.1%) [9] but significant variation in age will be a major confounding factor for MA. By looking at the period of study, most studies started in mid to late 2020 and concluded in 2021 with two studies completed in March and May 2022. During this period, different variants of SARS-CoV-2 virus emerged and the authors of 8 RCTs did not mentioned which strain of viruses they were looking at. We think that it could be more than 1 strains present in most (or all) of the studies. This is because most of the SARS-CoV-2 strains emerged in 2020 with Omicron in 2021 [10]. Out of 8 RCTs, five of them categorised as low RoB. Three RCTs with open label type of study were revealed to have high RoB. This is because in open label study, both drug administrator and study participants are alert of drug and treatment given [11]. This will lead to bias to the outcome of the results.

Based on grading the evidences, the inclusion and exclusion of high RoB article led to moderate and high certainty of evidences, respectively (table 2). Inclusion of only high RoB articles produced moderate certainty of evidences. These 2 level of certainties in 3 different analyses gave different impressions of MA. In figure 1A where the moderate certainty present, the heterogeneity was low with I² = 23% and p = 0.25. Fixed effect model was selected for the analysis. Treatment with baricitinib statistically significantly reduced mortality with the RR = 0.84 [95% CI: 0.76 to 0.92; p = 0.0002]. Although statistically significant, but since 3 high RoB articles present in the analysis, this analysis must be carefully interpreted. One of the ways to interpret is to look at table 1 and 2. The RoB and the certainty based on grading. When the RoB is high the certainty level is downgraded thus, leads to moderate quality/certainty of output due to performance bias in 3 included studies.

Excluding 3 high RoB studies from the main analysis is another option to derive a solid conclusion for mortality which is based on 5 low RoB studies. Based on the calculated optimal information size (OIS) for figure 1B (data not shown), inclusion of 5 low RoB studies provided optimal information to derive conclusion. The total 3944
sample size in figure 2B yielded the required OIS. In fact, according to Eli Lilly, approximately 1 million patients received baricitinib for the management of COVID-19 disease in 15 countries [12]. With the margin of error of 2.5% and confidence = 95%, the sample size of 3944 represents a population of minimum 300 million [13]. In figure 1B, treatment with baricitinib statistically significantly reduced mortality with the RR = 0.68 [95% CI: 0.56 to 0.82; p < 0.0001; I² = 0%; p = 0.85] with no heterogeneity was found. Based on figure 1B, with the presence of optimal sample size of 3944 from 5 low RoB studies which represents a minimum of 300 million population of people, the effectiveness of 2 mg or 4 mg baricitinib in reducing the mortality in COVID-19 patients was concretely proven. Despite large sample size, low heterogeneity, and significant reduction of mortality (p=0.04) by baricitinib in figure 1C but due to high performance bias and some other unclear biases, the effect of baricitinib in open-labelled RCTs need to be evaluated cautiously. Furthermore, RECOVERY study contributed the greatest number of participants plus events and the weightage of the study was 90.7% with the remaining weightage of just 8.3% is shared by another 2 small studies in figure 1C. Besides, based on table 1, karampitsakos [21] and PANCOVID/Montejano [22] produced different outcomes where the former mentioned baricitinib statistically reduced mortality while the latter mentioned the opposite. Based on the MA of these 2 studies, baricitinib statistically did not reduce mortality (data not shown) in COVID-19 patients where the RR = 0.76 [95% CI: 0.55 to 1.05; p = 0.1; I² = 0%; p = 0.35]. With the margin of error of 2.5% and confidence = 95%, the total sample size of 538 in both studies represented just 800-1000 actual population [13]. Based on our observation, with the weightage of almost 91%, the produced result in figure 1C is mostly belongs to 1 study which is RECOVERY and the MA output should not be considered or used for any clinical interpretation by clinicians and/or by policy-makers. In conclusion, the availability of additional 4 RCTs helped to solve the high heterogeneity and RoB issues found in the previously published article in order to derive a concrete conclusion on the effectiveness of baricitinib in reducing mortality in COVID-19 patients.

Conflict of interest
None

Funding
No funding received to construct this work. In case of open access publication, the publication fee will be provided by the Institute for Medical Research (IMR), National Institutes of Health, Ministry of Health, Malaysia.
Acknowledgement

The author would like to thank the Director General of Health Malaysia for his permission to publish this article, and the Director of the Institute for Medical Research for his support.

Supplementary Description

The supplementary files are given separately as supplementary file S1 (PRISM flow chart [14] of article inclusion and exclusion).

References


<table>
<thead>
<tr>
<th>Study</th>
<th>Study design &amp; phase</th>
<th>Period of study</th>
<th>Country</th>
<th>Population and age (B vs C)</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Cochrane RoB</th>
</tr>
</thead>
</table>
| RECOVERY [15] | RCT-open label & platform trial      | Feb 21-Dec 21   | 1 country | >100 centres/hospitals (58.5 vs 57.7) | i) 4mg baricitinib for 10 days  
ii) Reduced dose in case of low eGFR (<60mL/min) or patients taking probenecid or in children <9-year-old | Usual care | Mortality: Reduced | High (due to open label study design) |
| ACTT-2 [16]   | Full RCT & phase III trial           | May-July 20     | 8 countries | 67 centres (55 vs 55.8)       | i) Baricitinib 4mg (maximum 14 days)  
ii) Baricitinib 2mg (with other health related problems) (maximum 14 days) | Remdesivir  | Mortality: Not reduced | Low         |
| COV-BARRIER   | Full RCT & phase III trial           | Jun 20-Jan 21   | 12 countries | >100 centres (57.8 vs 57.5)   | Baricitinib 2mg or 4mg with matching SOC for maximum 14 days | Placebo with SOC | Mortality: Reduced | Low         |
| COV-BARRIER SEVERE [18] | Full RCT & phase III trial          | Dec 20-Apr 21   | 4 countries | 18 centres (58.4 vs 58.8)     | Baricitinib 2mg or 4mg with SOC for maximum 14 days | Placebo with SOC | Mortality: Reduced | Low         |
| ACTT-4 [19]   | Full RCT & phase III trial           | Dec 20-Apr 21   | 5 countries | 67 centres (58.2 vs 58.5)     | Baricitinib (4 mg or reduced dose in case of low eGFR for 14 days/death) plus remdesivir (200 mg loading dose then 100 mg maintenance dose for up to 10 days/discharge/death) plus placebo | Dexamethasone (6 mg for up to 10 days/discharge/death plus remdesivir plus placebo) | Mortality: Not reduced | Low         |
| EU-SolidAct   | Full RCT & phase III trial           | Jun 21-Mar 22   | 10 countries | 39 centres (59 vs 60)         | Baricitinib (4 mg) with SOC for up to 14 days | Matching placebo with SOC for up to 14 days | Mortality: Not reduced | Low         |
| Karampitsakos  | RCT-open label                      | Oct 21-May 22   | 1 country  | 3 centres (73 vs 72)          | i) Baricitinib (4 mg) for up to 14 days or until discharge.  
ii) Baricitinib (2 mg) in low eGFR | Tocilizumab (8 mg/kg i.v) and second infusion within 48-h in case of rapid health deterioration | Mortality: Reduced | High (due to open label study design) |
| PANCOVID/Montejano [22] | RCT-open label & phase III pragmatic trial | Oct 20-Sept 21 | 1 country  | 25 centres (68 vs 67)         | i) Baricitinib (4 mg) for 10-14 days with SOC  
ii) Baricitinib (2 mg) for patients >75-year-old | Dexamethasone (6 mg oral or i.v) for 7-10 days | Mortality: Not reduced | High (due to open label study design) |

**IMV:** Invasive mechanical ventilation; **SOC:** Standard of Care; **B:** Baricitinib; **C:** Control; **RoB:** Risk of bias; **UK:** United Kingdom; **eGFR:** Estimated glomerular filtration rate; **ECMO:** Extracorporeal membrane oxygenation; **NA:** Not available; **i.v:** intravenous. The outcomes were based on the statistical significance.
Table 2: Grading the evidence with GRADEpro Guideline Development Tool

<table>
<thead>
<tr>
<th>No of patients</th>
<th>Effect</th>
<th>Certainty</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of studies</td>
<td>Study design</td>
<td>Risk of bias</td>
<td>Inconsistency</td>
</tr>
<tr>
<td>Mortality 8 RCTs Mixed RoB</td>
<td>8 Randomised trials</td>
<td>Serious*</td>
<td>Not serious</td>
</tr>
<tr>
<td>Mortality 5 RCTs Low RoB</td>
<td>5 Randomised trials</td>
<td>Not serious</td>
<td>Not serious</td>
</tr>
<tr>
<td>Mortality 3 RCTs High RoB</td>
<td>3 Randomised trials</td>
<td>Serious*</td>
<td>Not serious</td>
</tr>
</tbody>
</table>

CI: confidence interval; RR: risk ratio

Explanations
a. Open label study

---

CI: confidence interval; RR: risk ratio

Explanations
a. Open label study
Figure 1: The outcome of baricitinib on mortality. (A) The MA of all included articles with and without RoB. (B) The MA of low RoB articles. (C) The MA of high RoB articles. On 29 October 2022, Karampitsakos [21] was contacted to clarify on whether the authors employed blind strategy for outcome assessment. The corresponding author replied yes, they did the blinding strategy to assess the outcome of the work. The similar email was sent to PANCOVID/Montejano [22] but no reply received.
Supplementary file 1: PRISM flow chart [14] of article inclusion and exclusion